SNOA (MC $22 M) (Cash $13 M) Lots of Products Marketed

They got another FDA approval for a new Product 2 weeks ago for which there was no press release because of competitive reasons , and many more Approvals expected in Brazil this year and may in Asia as well .This Stock is more than terrible underpriced with a laughable valuation of around $23 million .


Management bought some shares in last days
openinsider.com/search?q=snoa


Transcript of the conference last week
seekingalpha.com/article/4098556-sonoma-pharmaceuticals-snoa-ceo-jim-schutz-fiscal-q1-2018-results-earnings-call-transcript

Dermatology prescriptions filled for the first quarter were up 66% over last year and up 24% even versus the March 2017 quarter.

Our growing sales team now totals 30 sales reps and 5 managers. All reps have been trained, are out in the field generating prescriptions, and we are pleased to see the team hitting new weekly sales records for prescriptions filled at the pharmacy counter almost every week.

From a clinical trial perspective, we saw a publication of two studies, describing the benefits of Celacyn, our prescription scar management product, and for Sebuderm for the treatment of facial and scalp seborrheic dermatitis. Both studies are available online, in print and are great tools for our growing sales force when speaking with our customers, the dermatologists.

Our profit center businesses, which we define as our international business, acute care, animal health and our contract lab testing, are all on track for profitable growth for our full fiscal year.

And finally, our cash is healthy and we have almost no debt.

As Bob and I discuss often, it's a great time to be running this growing company with a dedicated team, all pushing towards the same goals and objectives.

Switching gears, a brief look ahead. Loyon, our skin descaling product, licensed from a German pharma company, was recently approved by the FDA and is on track for a launch in October.

You may have seen, we just received our 17th FDA approval last week for a new product and a new indication. For competitive reasons, we're not in a position to discuss this product or the timing for the launch. But suffice it to say that we should have an active nine months ahead with the FDA.

In Brazil, the regulatory equivalent of the FDA, which is Anvisa, asked us for more information on our pending dermatology products in the June timeframe. We've already answered their questions and provided all requested information.

We now expect up to seven new dermatology product approvals – and I'm going to repeat that, not launches, but approvals – specifically for the Brazilian dermatology market this fall.

As you'll no doubt remember, Brazil has become the world's third-largest market for beauty products after the US and Japan. And in plastic surgery and in dermatology procedures, Brazil is now the world's second-biggest market after the US.

Additionally, we have a handful of new approvals pending in the Middle East and in China. And we look forward to providing you with more information on our international dermatology growth soon.

So, in closing, we had a strong quarter due to our team's focus on our execution. We are well positioned for the remainder of this year and beyond.

Great! Where can I get the article like this? Thanks for sharing anyway.

I was out of this stock a few weeks ago because i needed that money to go all in KTOV which thank god paid off for me now im back in this terrible undervalued low float stock .Below is a new analysis by Stonegate . GL

Sonoma Pharma (Nasdaq: SNOA)

Marketcap: 19.6 Million
Cash: $12.6 Million
Price: $4.55

Book Value: $4.32
Annual Revenue on track to hit $16 Million

Shares Out : 4.3 Million

Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) ..October 18, 2017
pr.report/78EFCjq0

As of 6/30/17, the Company reported $3.8M in total revenue for Q1 FY18, with product revenues up 49% year-over-year driven by growth in US dermatology and acute care markets and in products sold to new owner of Latin American assets, and with approximately $12.6M in cash on hand and minimal debt. On an EV/R basis, Sonoma currently trades at 0.2x vs. the median of its peers at 34.5x based on FY18 estimates. In addition, companies in the dermatology space have been acquired at a median EV/R multiple of 3.6x. See full report for additional details.

Great News out today ...

Sonoma Pharmaceuticals Receives Brazilian Approvals to Market Multiple Hypochlorous Acid-Based Dermatology Products
finance.yahoo.com/news/sonoma-pharmaceuticals-receives-brazilian-approvals-114500685.html

Brazilian Dermatology Market Second Largest in the World Behind the United States

PETALUMA, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced the issuance of regulatory approvals by the Brazilian Ministério da Saúde for seven of Sonoma’s non-steroidal and non-antibiotic topical dermatology products:

Gramaderm® Hydrogel – intended as a skin cleanser after treatment of mild to moderate acne.
Gramaderm® – intended as a skin cleanser in a hydrogel vehicle after treatment of mild to moderate acne.
Epicyn™ – intended as a scar treatment.
Pediacyn™ – intended as an atopic dermatitis treatment.
Pediacyn™ Gel – intended as an atopic dermatitis treatment in a gel vehicle.
Lasercyn™ – intended as a skin cleanser following cosmetic procedures such as laser skin resurfacing.
Lasercyn™ Hydrogel – intended as a skin cleanser in a hydrogel vehicle following cosmetic procedures such as laser skin resurfacing.

“My Brazilian counterparts now have treatment options that can either replace or complement the standard protocols. In my practice I use Sonoma’s products for healing and as a steroid-sparing agent, anti-pruritic and anti-inflammatory,” said Dr. Miriam Bettencourt, assistant clinical professor of dermatology at the University of Nevada and adjunct professor of dermatology at Touro University in Las Vegas. “Having studied medicine in Brazil and with many of my colleagues practicing dermatology in Brazil, Sonoma’s new approvals should provide additional non-steroidal and non-antibiotic alternatives much like I use in here in the United States.”

Sonoma Pharmaceuticals is currently seeking to partner with a Brazilian healthcare company relative to licensing these newly approved products in the Brazilian dermatology space.

“We see the Brazilian dermatology market as being highly lucrative in terms of ongoing ramping revenue,” said Bruce Thornton, Sonoma’s VP of international sales. “Brazilian dermatologists are cutting edge when it comes to general dermatology and aesthetic procedures, and the addition of seven new hypochlorous acid-based products provides new alternatives for physicians worried about the side effects of topical steroids and resistance issues with the overuse of antibiotics.”

About the Brazilian Dermatology Market
According to BCC Research, skin conditions are among the most common health problems in most national populations, collectively exceeding the prevalence of conditions such as obesity, hypertension and cancer. The considerable costs of skin diseases include physician visits, hospital care, prescription drugs and over-the-counter products for treating or managing these conditions, as well as indirect costs due to productivity losses.

The global market for skin disease treatment technologies is estimated to reach $20.4 billion in 2020. The U.S market is the largest segment and should reach $8.6 billion in 2020. The BRIC (Brazil, Russia, India, China) countries are the fastest growing region of the global dermatology market and should total more than $4.6 billion by 2020.